<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6084">
  <stage>Registered</stage>
  <submitdate>10/12/2013</submitdate>
  <approvaldate>10/12/2013</approvaldate>
  <nctid>NCT02012179</nctid>
  <trial_identification>
    <studytitle>SODIUM-HF: Study of Dietary Intervention Under 100 MMOL in Heart Failure</studytitle>
    <scientifictitle>The Long Term Effects of Dietary Sodium Restriction on Clinical Outcomes in Patients With Heart Failure</scientifictitle>
    <utrn />
    <trialacronym>SODIUM-HF</trialacronym>
    <secondaryid>MOP130275</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Heart Failure</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - Low sodium diet

Experimental: Low sodium diet - Low sodium diet (65 mmol or 1500 mg/day)

No Intervention: Usual Care - General advice to limit dietary sodium as it is provided during routine clinic practice


Other interventions: Low sodium diet
Low sodium diet (65 mmol or 1500 mg/day)

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Composite Clinical Outcomes - All-cause mortality, cardiovascular hospitalizations or cardiovascular emergency department visits</outcome>
      <timepoint>12 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Exercise capacity - Change in exercise capacity as measured by the 6-minute walk test (6MWT)</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>NYHA functional class - Change in NYHA class treated as a categorical variable</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of life - Change in quality of life assessed by the KCCQ</outcome>
      <timepoint>12 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Patients recruited if they are 18+ years or older, with confirmed diagnosis of HF
             (both reduced and preserved systolic function are eligible), NYHA class II-III, and
             willing to sign informed consent.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Subjects will be excluded if:

          -  Average dietary intake of &lt;1500 mg/ day by a quantitative or semi-quantitative method

          -  Serum sodium &lt;130mmol/L

          -  Renal failure (glomerular filtration rate &lt;30 mL/min)

          -  Hepatic failure

          -  Uncontrolled thyroid disorder

          -  Cardiac device (ICD or CRT) or revascularization procedure (PCI or CABG) in previous
             month or planned in next 3 months

          -  Hospitalization due to cardiovascular causes in previous 1 month

          -  Uncontrolled atrial fibrillation (resting heart rate &gt;90 bpm)

          -  Active malignancy

          -  Moderate-severe dementia

          -  Enrolled in another interventional research study

          -  Patients will be excluded, if in the opinion of the investigator, another condition
             exists that would preclude dietary compliance or compliance with the protocol.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3>The people assessing the outcomes</masking3>
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>1000</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2020</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>St. Vincent's Hospital - Darlinghurst</hospital>
    <postcode> - Darlinghurst</postcode>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Manitoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Nova Scotia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Chile</country>
      <state>Osorno</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Chile</country>
      <state>Temuco</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Mexico City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>University of Alberta</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>SODIUM-HF is a multicenter clinical trial in ambulatory patients with chronic HF to evaluate
      the efficacy of a low sodium containing diet on a composite clinical outcome composed of of
      all-cause mortality, cardiovascular hospitalizations and cardiovascular emergency department
      visits. The hypothesis of this study is that patients following a low-sodium containing diet
      will have fewer clinical events (fewer hospital readmissions or emergency department visits,
      longer survival) than those randomized to Usual Care.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02012179</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Justin Ezekowitz, MBBCh</name>
      <address>University of Alberta</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Eloisa Colin, PhD</name>
      <address />
      <phone />
      <fax />
      <email>sodiumhf@ualberta.ca</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>